0.00%
-0.18%
8.01%
-6.82%
18.29%
-42.81%
-42.52%
AI Spotlight on SYAB
Create a Free account
Company Description
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.The company offers Coronavirus tests, and medical and veterinary diagnostics services.It operates through approximately 500 laboratories and 1,800 blood collection points in 36 countries in four continents.
The company was founded in 1998 and is headquartered in Munich, Germany.
Market Data
| Last Price | 11.06 |
| Change Percentage | -0.18% |
| Open | 11.08 |
| Previous Close | 11.08 |
| Market Cap ( Millions) | 2431 |
| Volume | 140347 |
| Year High | 12.43 |
| Year Low | 8.02 |
| M A 50 | 10.84 |
| M A 200 | 11.02 |
Financial Ratios
| FCF Yield | 10.12% |
| Dividend Yield | 2.98% |
| ROE | 3.79% |
| Debt / Equity | 38.99% |
| Net Debt / EBIDTA | 259.34% |
| Price To Book | 1.02 |
| Price Earnings Ratio | 27.2 |
| Price To FCF | 9.88 |
| Price To sales | 0.93 |
| EV / EBITDA | 7.5 |
News
- Jun -18 - Is Now An Opportune Moment To Examine SYNLAB AG (ETR:SYAB)?
- Jun -04 - London Hospitals Hit by Cyberattack Impacting Blood Transfusions
- May -11 - SYNLAB First Quarter 2024 Earnings: EPS: €0.11 (vs €0.13 in 1Q 2023)
- Apr -29 - Declining Stock and Decent Financials: Is The Market Wrong About SYNLAB AG (ETR:SYAB)?
- Nov -29 - At €11.25, Is SYNLAB AG (ETR:SYAB) Worth Looking At Closely?
- Oct -27 - Kuehne + Nagel International (VTX:KNIN) Is Aiming To Keep Up Its Impressive Returns
- Jun -18 - APG|SGA (VTX:APGN) Has Some Difficulty Using Its Capital Effectively
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Human Medicine
Expected Growth : 9 %
What the company do ?
Human Medicine from SYNLAB AG refers to the diagnosis and treatment of diseases in humans, utilizing advanced laboratory testing and medical expertise.
Why we expect these perspectives ?
SYNLAB AG's Human Medicine segment growth is driven by increasing demand for diagnostic services, expansion into new markets, and strategic acquisitions. Additionally, the company's focus on innovative testing solutions, digitalization, and personalized medicine contributes to its 9% growth rate.
Segment n°2 -> Veterinary Medicine
Expected Growth : 7 %
What the company do ?
Veterinary Medicine from SYNLAB AG provides diagnostic services and laboratory testing for animal health, supporting veterinarians in diagnosing and treating animal diseases.
Why we expect these perspectives ?
The 7% growth in Veterinary Medicine from SYNLAB AG is driven by increasing pet ownership, rising demand for animal health services, and advancements in diagnostic technologies. Additionally, the growing need for disease surveillance and monitoring, as well as the increasing importance of animal health in the food chain, contribute to this growth.
Segment n°3 -> Trading Goods and Services
Expected Growth : 6 %
What the company do ?
SYNLAB AG's Trading Goods and Services segment involves the sale of laboratory equipment, consumables, and services to external customers.
Why we expect these perspectives ?
SYNLAB AG's 6% growth in Trading Goods and Services is driven by increasing demand for diagnostic services, expansion into new markets, and strategic partnerships. Additionally, investments in digitalization and automation have improved operational efficiency, enabling the company to capitalize on growing healthcare expenditure and an aging population.
Segment n°4 -> Environmental and Other Analysis, Studies, Expertise
Expected Growth : 5 %
What the company do ?
Environmental and Other Analysis, Studies, Expertise from SYNLAB AG provides comprehensive testing, inspection, and certification services for environmental, food, and pharmaceutical industries.
Why we expect these perspectives ?
SYNLAB AG's 5% growth is driven by increasing demand for environmental testing and analysis, expansion into emerging markets, and strategic acquisitions. The company's expertise in providing comprehensive laboratory services, including water, air, and soil testing, positions it for growth in the environmental sector. Additionally, SYNLAB's investment in digitalization and automation enhances operational efficiency, further supporting its growth trajectory.
Segment n°5 -> Software Solutions and Services
Expected Growth : 8 %
What the company do ?
SYNLAB AG's Software Solutions and Services provide laboratory information systems, data analytics, and digital healthcare solutions to support medical diagnostics and research.
Why we expect these perspectives ?
SYNLAB AG's Software Solutions and Services segment growth is driven by increasing demand for digital healthcare solutions, expansion into new markets, strategic partnerships, and investments in AI-powered diagnostic tools. Additionally, the growing need for data analytics and interoperability in healthcare systems, as well as the rising adoption of cloud-based services, contribute to the segment's 8% growth.
Synlab Ag Products
| Product Range | What is it ? |
|---|---|
| Human Diagnostics | SYNLAB AG offers a wide range of diagnostic tests and services for human health, including molecular diagnostics, microbiology, and pathology. |
| Veterinary Diagnostics | SYNLAB provides diagnostic services for animal health, including testing for diseases, parasites, and contaminants in animals. |
| Environmental Diagnostics | SYNLAB offers testing and analysis services for environmental samples, including water, air, and soil, to detect contaminants and pollutants. |
| Food Diagnostics | SYNLAB provides testing and analysis services for food and beverages, including detection of contaminants, allergens, and adulterants. |
| Pharma and Biotech Services | SYNLAB offers specialized testing and analysis services for the pharmaceutical and biotechnology industries, including bioanalysis, biomarker testing, and clinical trials support. |
SYNLAB AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for SYNLAB AG is moderate due to the presence of alternative diagnostic services and products.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of SYNLAB AG's services and the lack of alternative providers.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers of diagnostic equipment and reagents.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the diagnostic services industry, including regulatory hurdles and the need for specialized expertise.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established players in the diagnostic services industry, leading to intense competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 31.20% |
| Debt Cost | 8.41% |
| Equity Weight | 68.80% |
| Equity Cost | 8.41% |
| WACC | 8.41% |
| Leverage | 45.35% |
SYNLAB AG : Quality Control
SYNLAB AG passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| QIA.DE | QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for … |
| ERF.PA | Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, … |
| BIM.PA | bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers … |
| DIA.MI | DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Qiagen
A-Score
1-Year Total Return ->
🥉
Synlab
A-Score
1-Year Total Return ->
4
DiaSorin
A-Score
1-Year Total Return ->
5
bioMérieux
A-Score
1-Year Total Return ->
6
